ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZYME ZYMEWORKS INC (US)

Post-Mkt 03-13 16:20:37 EDT

22.88

-0.35

-1.51%

盘后22.88

+0.000.00%

16:10 EDT

High23.89	Low22.43	Vol785.02K
Open23.42	D1 Closing23.23	Amplitude6.29%
Mkt Cap1.69B	Tradable Cap876.29M	Total Shares73.75M
T/O17.96M	T/O Rate2.05%	Tradable Shares38.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":22.88,"timestamp":1773432000000,"preClose":23.23,"halted":0,"volume":785020,"hourTrading":{"tag":"盘后","latestPrice":22.88,"preClose":22.88,"latestTime":"16:10 EDT","volume":17160,"amount":392620.8,"timestamp":1773432605512,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01506672406371078,"floatShares":38299500,"shares":73749607,"eps":-1.08,"marketStatus":"Post-Mkt","change":-0.35,"latestTime":"03-13 16:20:37 EDT","open":23.42,"high":23.89,"low":22.43,"amount":17962001.35531,"amplitude":0.06285,"askPrice":23.33,"askSize":85,"bidPrice":22.44,"bidSize":89,"shortable":3,"etf":0,"ttmEps":-1.08,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773446400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":23.23,"preHourTrading":{"tag":"盘前","latestPrice":23.31,"preClose":23.23,"latestTime":"09:20 EDT","volume":2146,"amount":49920.099634,"timestamp":1773408058574,"change":0.08,"changeRate":0.003444,"amplitude":0.048644},"postHourTrading":{"tag":"盘后","latestPrice":22.88,"preClose":22.88,"latestTime":"16:10 EDT","volume":17160,"amount":392620.8,"timestamp":1773432605512,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.735264,"impliedVol":0.721,"impliedVolPercentile":0.5578},"requestUrl":"/m/hq/s/ZYME/tweets","defaultTab":"tweets","newsList":[{"id":"2618132332","title":"Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618132332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618132332?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:30","pubTimestamp":1773318622,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GeneDx Holdings (WGS – Research Report) and Zymework...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genedx-holdings-wgs-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genedx-holdings-wgs-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XLV","LU0128526141.USD","BK4196","HCSG","BK4585","BK4137","LU0029874061.USD","LABU","ZYME","XBI","WGS","BK4139","BK4581"],"gpt_icon":0},{"id":"2618787206","title":"Zymeworks Is Maintained at Outperform by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2618787206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618787206?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:30","pubTimestamp":1773073800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZYME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 12:30 ET (16:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2618976656","title":"Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976656","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976656?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:19","pubTimestamp":1773015564,"startTime":"0","endTime":"0","summary":"Zymeworks (($ZYME)) has held its Q4 earnings call. Read on for the main highlights of the call. Zymeworks’ latest earnings call struck an upbeat to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zymeworks-earnings-call-zanidatumab-drives-bullish-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zymeworks-earnings-call-zanidatumab-drives-bullish-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","ZYME","BK4112","BLSX"],"gpt_icon":0},{"id":"2617957687","title":"Zymeworks Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617957687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617957687?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:14","pubTimestamp":1772799240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZYME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 07:14 ET (12:14 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"1154856625","title":"Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=1154856625","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154856625?lang=en_us&edition=fundamental","pubTime":"2026-03-04 03:24","pubTimestamp":1772565882,"startTime":"0","endTime":"0","summary":"Zymeworks Inc (ZYME) saw its stock price surge 5.45% during Tuesday's intraday trading session, driven by a wave of positive analyst sentiment.Multiple financial institutions issued favorable ratings...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZYME"],"gpt_icon":0},{"id":"2616322299","title":"Zymeworks Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2616322299","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616322299?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:30","pubTimestamp":1772555400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZYME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 11:30 ET (16:30 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2616347080","title":"Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347080","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347080?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:37","pubTimestamp":1772541440,"startTime":"0","endTime":"0","summary":"In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Zymeworks, with a price target of $40.00. Accordi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME"],"gpt_icon":0},{"id":"2616347089","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347089?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541013,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veeva Systems (VEEV – Research Report), Zymeworks (ZYME – Researc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-veeva-systems-veev-zymeworks-zyme-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-veeva-systems-veev-zymeworks-zyme-and-senseonics-holdings-sens-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0266013472.USD","LU0029874061.USD","BK4167","BK4528","LU0128526141.USD","LU1989764748.USD","BK4082","ZYME","VEEV","LU1989764664.SGD","HCSG","BK4137","XBI","XLV","BK4613","SENS","BK4588","BK4139","LU0170899867.USD","BK4581","BK4585","LU0058720904.USD","BK4534","BK4504","LABU","LU0289739699.SGD"],"gpt_icon":0},{"id":"2616347037","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347037?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:30","pubTimestamp":1772541011,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks, with a price target of $47.00. Willey covers ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-zymeworks-zyme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","ZYME"],"gpt_icon":0},{"id":"2616313458","title":"Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2616313458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616313458?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:00","pubTimestamp":1772517621,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) has disclosed a new risk, in the Corporate Activity and Growth category. Zymeworks faces significant uncertainty because its long-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zymeworks-growth-clouded-by-high-clinical-failure-risk-and-regulatory-uncertainty?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zymeworks-growth-clouded-by-high-clinical-failure-risk-and-regulatory-uncertainty?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2616353251","title":"Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353251","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616353251?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:31","pubTimestamp":1772461894,"startTime":"0","endTime":"0","summary":"Zymeworks Inc reports results for the quarter ended December 31 - Earnings SummaryZymeworks Inc ZYME.OQ reported a quarterly adjusted loss of 55 cents per share for the quarter ended December 31, lowe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL8N3ZQ20S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2616358502","title":"Zymeworks Publishes Corporate Presentation on Royalty-Driven Growth Strategy and Oncology Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2616358502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616358502?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:02","pubTimestamp":1772460173,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. released a corporate presentation outlining recent partnership and pipeline updates. The company reported recognized research revenue of $2.5 million and recognized revenue of $25.2 million in partnership milestone payments, including milestone payments tied to regulatory progress for Ziihera for HER2-positive biliary tract cancer and a $25.0 million development milestone payment from Johnson and Johnson. The presentation also highlights ongoing development programs, including Phase 1 trials for ZW191 and ZW251, and notes a decision to discontinue development of ZW171. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL2xzrbJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2471134796.USD","LU1162221912.USD","LU1066053197.SGD","LU0203345920.USD","LU1066051225.USD","IE00BJJMRZ35.SGD","LU0689626769.HKD","LU2430703178.SGD","IE00BSNM7G36.USD","LU1023059063.AUD","LU1261432733.SGD","SG9999001440.SGD","LU2430703251.USD","IE0009355771.USD","IE0001KFT4U8.USD","IE00BJT1NW94.SGD","IE00BVYPNW00.USD","LU2129689605.HKD","LU1430594728.SGD","IE00B1BXHZ80.USD","LU2750360997.AUD","SG9999002232.USD","BK4534","LU0432979614.USD","LU1074936037.SGD","LU1894683264.USD","LU2592432038.USD","ZYME","LU1066051498.USD","BK4585","LU0889566641.SGD","LU0345769631.USD","JNJ","LU2112291526.USD","LU2471134952.CNY","LU2468319806.SGD","IE00BVYPNV92.GBP","IE00B19Z3581.USD","BK4504","BK4559","LU1674673691.USD","LU1244550221.USD","LU1894683348.USD","BK4581","LU1778281490.HKD","LU1267930813.SGD","LU1914381329.SGD","BK4588","LU0320765646.SGD"],"gpt_icon":0},{"id":"2616766336","title":"Zymeworks Q4 Net Loss Widens, Revenue Falls; Enters $250 Million Financing Agreement with Royalty Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2616766336","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616766336?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:35","pubTimestamp":1772451309,"startTime":"0","endTime":"0","summary":"Zymeworks  reported a Q4 net loss Monday of $0.55 per diluted share, widening from a loss of $0.31 a year earlier.Analysts polled by FactSet expected a loss of $0.46.Revenue for the quarter ended Dec. 31 was $2.5 million, compared with $31 million a year earlier.Analysts surveyed by FactSet expected $19.2 million.As of Dec. 31, the company said it had $270.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations beyond 2028.Additionally, Royalty Pharma  and Zymeworks  said Monday the companies have entered into a $250 million non-recourse royalty-backed note financing, with repayments tied to 30% of Zymeworks' worldwide tiered royalties on Ziihera.Under the agreement, Zymeworks will retain 70% of royalties from Ziihera sales during the repayment period, with full royalty rights reverting to the company once Royalty Pharma receives agreed cumulative payments, the companies said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYME","BK4139","RPRX","BK4007"],"gpt_icon":0},{"id":"2616335080","title":"Zymeworks, Royalty Pharma enter $250M royalty-backed note financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335080?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:15","pubTimestamp":1772450110,"startTime":"0","endTime":"0","summary":"Zymeworks (ZYME) and Royalty Pharma (RPRX) announced an agreement for $250M in funding from Royalty Pharma in the form of a non-recourse royalty-ba...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-royalty-pharma-enter-250m-royalty-backed-note-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-royalty-pharma-enter-250m-royalty-backed-note-financing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RPRX","BK4139","ZYME"],"gpt_icon":0},{"id":"2616233616","title":"Earnings Flash (ZYME) Zymeworks Posts Q4 Revenue $2.5M, vs. FactSet Est of $19.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2616233616","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616233616?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:11","pubTimestamp":1772449867,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZYME) Zymeworks Posts Q4 Revenue $2.5M, vs. FactSet Est of $19.2M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYME"],"gpt_icon":0},{"id":"2616335217","title":"Zymeworks reports Q4 EPS (55c) vs. (31c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335217","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335217?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:10","pubTimestamp":1772449850,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $2.5M vs. $31M last year. “Over the past year, we have redefined our approach to what success can look like at Zymeworks (ZYME)....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-reports-q4-eps-55c-vs-31c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-reports-q4-eps-55c-vs-31c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2616336147","title":"Earnings Flash (ZYME) Zymeworks Posts Q4 Net Loss $0.55 a Share, vs. FactSet Est of $0.46 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336147","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336147?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:09","pubTimestamp":1772449789,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZYME) Zymeworks Posts Q4 Net Loss $0.55 a Share, vs. FactSet Est of $0.46 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZYME"],"gpt_icon":0},{"id":"2616335665","title":"Canada's Zymeworks 2025 revenue rises 39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335665","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335665?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:08","pubTimestamp":1772449711,"startTime":"0","endTime":"0","summary":"Canada's Zymeworks 2025 revenue rises 39%OverviewBiotechnology firm's 2025 revenue rose 39% yr/yr, driven by clinical milestonesNet loss for 2025 reduced by 34% compared to previous yearCompany utiliz","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nL1N3ZQ0EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX","ZYME","BK4007","BK4139"],"gpt_icon":0},{"id":"2616355413","title":"Zymeworks Q4 2025 EPS $(0.55) Misses $(0.42) Estimate, Sales $2.515M Miss $13.576M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355413","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616355413?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:04","pubTimestamp":1772449469,"startTime":"0","endTime":"0","summary":"Zymeworks Q4 2025 EPS $(0.55) Misses $(0.42) Estimate, Sales $2.515M Miss $13.576M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/50958784/zymeworks-q4-2025-eps-0-55-misses-0-42-estimate-sales-2-515m-miss-13-576m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"2616335813","title":"Zymeworks and Royalty Pharma Enter Into $250 Million Royalty-Backed Note Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335813?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:01","pubTimestamp":1772449287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ0K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ZYME","RPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":-0.0633},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.0883},{"period":"6month","weight":0.4759},{"period":"1year","weight":0.8917},{"period":"ytd","weight":-0.1177}],"compareEarnings":[{"period":"1week","weight":-0.0224},{"period":"1month","weight":-0.0377},{"period":"3month","weight":-0.023},{"period":"6month","weight":0.0132},{"period":"1year","weight":0.1918},{"period":"ytd","weight":-0.0233}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.015488},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.056871},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.02951},{"month":4,"riseRate":0.625,"avgChangeRate":0.039222},{"month":5,"riseRate":0.333333,"avgChangeRate":0.017913},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.046141},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.030946},{"month":8,"riseRate":0.888889,"avgChangeRate":0.104131},{"month":9,"riseRate":0.444444,"avgChangeRate":0.038592},{"month":10,"riseRate":0.666667,"avgChangeRate":0.043198},{"month":11,"riseRate":0.777778,"avgChangeRate":0.135367},{"month":12,"riseRate":0.555556,"avgChangeRate":0.004939}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ZYMEWORKS INC (US)(ZYME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction